Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States

2.

Leebeek

FW

,

Eikenboom

JC

.

Von Willebrand's disease

.

N Engl J Med

.

2016

;

375

(

21

):

2067

-

2080

.

3.

Connell

NT

,

Flood

VH

,

Brignardello-Petersen

R

, et al.

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

.

Blood Adv

.

2021

;

5

(

1

):

301

-

325

.

4.

Miesbach

W

,

Berntorp

E

.

Translating the success of prophylaxis in haemophilia to von Willebrand disease

.

Thromb Res

.

2021

;

199

:

67

-

74

.

5.

Leebeek

FWG

,

Peyvandi

F

,

Escobar

M

, et al.

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results

.

Blood

.

2022

;

140

(

2

):

89

-

98

.

6.

Centers for Medicare & Medicaid Services

.

ASP drug pricing files January 2024 update

. Accessed 18 January 2024. https://www.cms.gov/medicare/payment/all-fee-service-providers/medicare-part-b-drug-average-sales-price/asp-pricing-files.

7.

Centers for Medicare & Medicaid Services

.

CMS physician fee schedule

. 2023. Accessed 20 June 2023. https://www.cms.gov/medicare/physician-fee-schedule/search?Y=1&T=4&HT=0&CT=3&H1=96365&M=5.

8.

Centers for Medicare & Medicaid Services

.

FY 2022 IPPS final rule home page

. Accessed 21 June 2023. https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/fy-2022-ipps-final-rule-home-page#Reg.

9.

Machin

N

,

Ragni

MV

,

Smith

KJ

.

Gene therapy in hemophilia A: a cost-effectiveness analysis

.

Blood Adv

.

2018

;

2

(

14

):

1792

-

1798

.

10.

Sanders

GD

,

Neumann

PJ

,

Basu

A

, et al.

Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine

.

JAMA

.

2016

;

316

(

10

):

1093

-

1103

.

11.

Kim

DD

,

Silver

MC

,

Kunst

N

,

Cohen

JT

,

Ollendorf

DA

,

Neumann

PJ

.

Perspective and costing in cost-effectiveness analysis, 1974-2018

.

Pharmacoeconomics

.

2020

;

38

(

10

):

1135

-

1145

.

12.

Gill

JC

,

Castaman

G

,

Windyga

J

, et al.

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

.

Blood

.

2015

;

126

(

17

):

2038

-

2046

.

13.

Trossaërt

M

,

Flaujac

C

,

Jeanpierre

E

, et al.

Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease

.

Haemophilia

.

2020

;

26

(

2

):

e44

-

e48

.

14.

Bauer

A

,

Friberg-Hietala

S

,

Smania

G

,

Wolfsegger

M

.

Pharmacokinetic-pharmacodynamic comparison of recombinant and plasma-derived von Willebrand factor in patients with von Willebrand disease type 3

.

J Blood Med

.

2023

;

14

:

399

-

411

.

15.

Thornburg

CD

,

Carpenter

S

,

Zappa

S

,

Munn

J

,

Leissinger

C

.

Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States

.

Haemophilia

.

2012

;

18

(

4

):

568

-

574

.

16.

Furlan

R

,

Krishnan

S

,

Vietri

J

.

Patient and parent preferences for characteristics of prophylactic treatment in hemophilia

.

Patient Prefer Adherence

.

2015

;

9

:

1687

-

1694

.

17.

Franchini

M

,

Seidizadeh

O

,

Mannucci

PM

.

Prophylactic management of patients with von Willebrand disease

.

Ther Adv Hematol

.

2021

;

12

:

20406207211064064

.

18.

Flood

VH

,

Abshire

TC

,

Christopherson

PA

, et al.

Von Willebrand disease in the United States: perspective from the Zimmerman program

.

Ann Blood

.

2018

;

3

(

1

):

7

.

19.

Hanna

WT

,

Bona

RD

,

Zimmerman

CE

,

Carta

CA

,

Hebert

GZ

,

Rickles

FR

.

The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease

.

Thromb Haemost

.

1994

;

71

(

2

):

173

-

179

.